learn SCUBE3
a signaling molecule from dermal papilla cells being actively researched
Search
forLearn
5 / 801 resultslearn L-cysteine
learn copper tripeptide-1
learn KY19382
compound that activates Wnt/β-catenin to promote hair regrowth and create new hair follicles
learn Coix Seed
Research
5 / 45 resultsresearch Association between DNA Methylation in the Core Promoter Region of the CUT-like Homeobox 1 (CUX1) Gene and Lambskin Pattern in Hu Sheep
DNA methylation likely doesn't cause different lambskin patterns in Hu sheep.
research SP1 and KROX20 Regulate the Proliferation of Dermal Papilla Cells and Target the CUX1 Gene
SP1 promotes and KROX20 inhibits hair cell growth by affecting the CUX1 gene.
research Genetic Ablation of the CDP/Cux Protein C Terminus Results in Hair Cycle Defects and Reduced Male Fertility
Mutant CDP/Cux protein causes hair defects and reduced male fertility in mice.
research Effect of CUX1 on the Proliferation of Hu Sheep Dermal Papilla Cells and on the Wnt/β-Catenin Signaling Pathway
CUX1 boosts sheep hair cell growth and affects curl patterns.
research Genetic prediction of male pattern baldness
Genetic factors can help predict male pattern baldness risk.
Community Join
5 / 1000+ resultscommunity Korean scientists breakthrough in hair regeneration targeting CXXC5 protein and WNT Signaling Pathway
A potential non-invasive topical treatment targeting the WNT Signaling Pathway for hair regeneration is being researched, with positive results on human hair follicle cells. Current effective treatments for hair loss include Minoxidil, finasteride, and hair transplantation.
community Expectations control for SCUBE3
SCUBE3, a protein linked to hair growth in moles, was discovered over 25 years ago and is being developed by Amplifica for potential hair loss treatment. Concerns exist about SCUBE3's association with cancer, as it is a protein that promotes cell growth, which could potentially trigger cancer development if used for hair growth therapy.
community Ruxolitinib - Start of a case study
The conversation is about a user trying a new hair loss treatment, Ruxolitinib, alongside their existing regimen of finasteride, minoxidil, ketoconazole shampoo, and microneedling. They plan to apply Ruxolitinib to their temples daily for 1-2 months.
community Selling KY19382 powder a novel activator of Wnt/β-catenin signaling Product
Selling KY19382 powder, a novel activator of Wnt/β-catenin signaling, and Kolliphor EL liquid for vehicle formulation. KY19382 is a growth agonist.
community KX-826 , a small change in the pipeline
KX-826 is undergoing trials for hair loss treatment, showing similar effectiveness between 0.5% and 1.0% dosages, with mild side effects compared to finasteride. Users discuss combining KX-826 with other treatments like minoxidil and clascoterone for better results.